Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(17):1311-1321; doi:10.1093/jnci/djh253
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (47)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Schairer, C.
Right arrow Articles by Devesa, S. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schairer, C.
Right arrow Articles by Devesa, S. S.
Related Collections
Right arrowRelated Memo to the Media
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

ARTICLE

Probabilities of Death From Breast Cancer and Other Causes Among Female Breast Cancer Patients

Catherine Schairer, Pamela J. Mink, Leslie Carroll, Susan S. Devesa

Affiliations of authors: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (CS, SSD); Exponent Health Group, Washington, DC (PJM); Information Management Services, Inc., Rockville, MD (LC)

Correspondence to: Catherine Schairer, PhD, National Cancer Institute, 6120 Executive Blvd., EPS Rm. 8020, MSC 7234, Rockville, MD 20852-7234 (e-mail: schairec{at}exchange.nih.gov)

Background: Among cancer patients, probabilities of death from that cancer and other causes in the presence of competing risks are optimal measures of prognosis and of mortality across demographic groups. We used data on breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) Program in a competing-risk analysis. Methods: We determined vital status and cause of death for 395 251 white and 35 259 black female patients with breast cancer diagnosed from January 1, 1973, through December 31, 2000, by use of SEER data. We calculated probabilities of death from breast cancer and other causes according to stage, race, and age at diagnosis; for cases diagnosed from January 1, 1990, to December 31, 2000, we also calculated some such probabilities according to tumor size and estrogen receptor (ER) status. All statistical tests were two-sided. Results: The probability of death from breast cancer after nearly 28 years of follow-up ranged from 0.03 to 0.10 for patients with in situ disease to 0.70 to 0.85 for patients with distant disease, depending on race and age. The probability of death from breast cancer at the end of the follow-up period generally declined with age at diagnosis; the probability among the oldest (≥70 years) compared with the youngest (<50 years) patients was 33% lower for white and 46% lower for black patients with localized disease and 14% lower for white patients and 13% lower for black patients with distant disease. The probability of death from breast cancer exceeded that from all other causes for patients diagnosed with localized disease before age 50 years, with regional disease before age 60 years, and with distant disease at any age. The probability of death from breast cancer for patients diagnosed with localized or regional disease was statistically significantly greater in black patients than in white patients (all six P values ≤.01 for age groups 30–49 to 60–69 years; two P values ≤.04 for ages ≥70 years). Among patients with localized or regional disease and known ER status, the probability of death from breast cancer after nearly 11 years of follow-up ranged from 0.04 to 0.11 for patients with localized ER-positive tumors of 2 cm or less to 0.37 to 0.53 for patients with regional ER-negative tumors. Conclusions: The probability of death from breast cancer versus other causes varied substantially according to stage, tumor size, ER status, and age at diagnosis in both white and black patients.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Memo to the Media

Press Release: Study Estimates Probability of Death After Breast Cancer Diagnosis
Sarah L. Zielinski
J Natl Cancer Inst 2004 96: 1263. [Extract] [Full Text]



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. M. Gaudet, M. Campan, J. D. Figueroa, X. R. Yang, J. Lissowska, B. Peplonska, L. A. Brinton, D. L. Rimm, P. W. Laird, M. Garcia-Closas, et al.
DNA Hypermethylation of ESR1 and PGR in Breast Cancer: Pathologic and Epidemiologic Associations
Cancer Epidemiol. Biomarkers Prev., November 1, 2009; 18(11): 3036 - 3043.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. K. Litton and A. M. Brewster
In Reply
J. Clin. Oncol., February 10, 2009; 27(5): 830 - 831.
[Full Text] [PDF]

Home page
 The OncologistHome page
M. Martin, F. J. Esteva, E. Alba, B. Khandheria, L. Perez-Isla, J. A. Garcia-Saenz, A. Marquez, P. Sengupta, and J. Zamorano
Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations
Oncologist, January 1, 2009; 14(1): 1 - 11.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. B. Muss, D. Tu, J. N. Ingle, S. Martino, N. J. Robert, J. L. Pater, T. J. Whelan, M. J. Palmer, M. J. Piccart, L. E. Shepherd, et al.
Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17
J. Clin. Oncol., April 20, 2008; 26(12): 1956 - 1964.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
S. H. Giordano and G. N. Hortobagyi
Time to Remove the Subspecialty Blinders: Breast Cancer Does Not Exist in Isolation
J Natl Cancer Inst, February 20, 2008; 100(4): 230 - 231.
[Full Text] [PDF]

Home page
 JCOHome page
E. O. Hanrahan, A. M. Gonzalez-Angulo, S. H. Giordano, R. Rouzier, K. R. Broglio, G. N. Hortobagyi, and V. Valero
Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma
J. Clin. Oncol., November 1, 2007; 25(31): 4952 - 4960.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
M. E. Porter and E. O. Teisberg
Changing the Organization of Health Care--Reply
JAMA, July 18, 2007; 298(3): 287 - 288.
[Full Text] [PDF]

Home page
 JCOHome page
M. A. Thorat, V. Parmar, M. S. Nadkarni, and R. A. Badwe
Radiation Therapy for Ductal Carcinoma In Situ: Is It Really Worth It?
J. Clin. Oncol., February 1, 2007; 25(4): 461 - 462.
[Full Text] [PDF]

Home page
 JCOHome page
E. O. Hanrahan, V. Valero, A. M. Gonzalez-Angulo, and G. N. Hortobagyi
Prognosis and Management of Patients With Node-Negative Invasive Breast Carcinoma That Is 1 cm or Smaller in Size (stage 1; T1a,bN0M0): A Review of the Literature
J. Clin. Oncol., May 1, 2006; 24(13): 2113 - 2122.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. D. Schwartz, B. N. Peshkin, and C. Isaacs
In Reply:
J. Clin. Oncol., February 20, 2005; 23(6): 1331 - 1332.
[Full Text] [PDF]

Home page
 Br J OphthalmolHome page
From the library
Br J Ophthalmol, January 1, 2005; 89(1): 126 - 126.
[Full Text] [PDF]

Home page
 BMJHome page
Minerva
BMJ, October 23, 2004; 329(7472): 986 - 986.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.